Amicus Therapeutics Inc FOLD:NASDAQ

Last Price$11.14Cboe Real-Time Last Sale as of 1:36PM ET 12/01/21
Cboe Real-Time Quotes
Realtime quote and/or trade prices are not sourced from all markets
Today's Change+0.43(4.01%)
Bid (Size)$11.12 (300)
Ask (Size)$11.14 (221)
Day Low / High$10.93 - 11.38
Volume815.5 K
 

View Biotechnology IndustryPeer Comparison as of 12/01/2021

 

Amicus Therapeutics Inc ( NASDAQ )

Price: $11.14
Change: +0.43 (4.01%)
Volume: 815.5 K
1:36PM ET 12/01/2021
 
 

Dicerna Pharmaceuticals Inc ( NASDAQ )

Price: $38.14
Change: +0.13 (0.34%)
Volume: 2.2 M
1:32PM ET 12/01/2021
 
 

Veracyte Inc ( NASDAQ )

Price: $40.12
Change: -1.36 (3.28%)
Volume: 231.8 K
1:37PM ET 12/01/2021
 
 

Iovance Biotherapeutics Inc ( NASDAQ )

Price: $18.14
Change: -0.58 (3.10%)
Volume: 683.1 K
1:37PM ET 12/01/2021
 
 

N/A ( N/A )

Price: N/A
Change: N/A N/A
Volume: N/A
N/A
 

Read more news Recent News

Stifel Lifts Amicus Therapeutics to Buy From Hold, Price Target to $16 From $12
7:03AM ET 11/15/2021 MT Newswires

Amicus Therapeutics (FOLD) has an average rating of outperform and price targets ranging from $12 to $29, according to analysts polled by Capital IQ. (MT...

Amicus Therapeutics Narrows Q3 Loss as Revenue Rises
8:22AM ET 11/09/2021 MT Newswires

Amicus Therapeutics (FOLD) reported Tuesday a Q3 net loss of $0.19 per share, narrower than the $0.25 per share loss a year ago but still missing the...

SVB Leerink Adjusts Amicus Therapeutics PT to $12 from $13, Maintains Market Perform Rating
9:04AM ET 9/30/2021 MT Newswires

Amicus Therapeutics (FOLD) has an average investment rating of outperform among analysts polled by Capital IQ, with a price target range of $12 to $29. (MT...

JPMorgan Upgrades Amicus Therapeutics to Overweight From Neutral, Price Target at $16
7:37AM ET 9/30/2021 MT Newswires

Amicus Therapeutics (FOLD) has an average investment rating of outperform and price targets ranging from $12 to $29, according to analysts polled by...

Company Profile

Business DescriptionAmicus Therapeutics, Inc. operates as a biotechnology company. The firm focuses on discovering, developing and delivering medicines for people living with metabolic diseases. Its product portfolio includes first and only approved oral precision medicine for people living with Fabry disease who have amenable genetic variants, a novel, clinical-stage, treatment paradigm for Pompe disease and a rare disease gene therapy portfolio. The company was founded by John Francis Crowley on February 4, 2002 and is headquartered in Philadelphia, PA. View company web site for more details
Address3675 Market Street
Philadelphia, Pennsylvania 19104
Phone+1.215.921.7600
Number of Employees508
Recent SEC Filing11/18/20218-K
Chairman & Chief Executive OfficerJohn Francis Crowley
President, Chief Operating Officer & DirectorBradley Lewis Campbell
Chief Financial OfficerDaphne E. Quimi
Chief Science OfficerJill Weimer

Company Highlights

Price Open$10.93
Previous Close$10.71
52 Week Range$8.60 - 25.39
Market Capitalization$3.1 B
Shares Outstanding278.6 M
SectorHealth Technology
IndustryBiotechnology
Next Earnings Announcement03/07/2022

Options Summary

Call Open Interest (1d)*
Put Open Interest (1d)*
Call Volume (1d)*
Put Volume (1d)*
Put Call Open Interest Ratio (1d)*
Put Call Volume Ratio (1d)*
* Data delayed by up to 15 minutes

View all fundamentalsFundamentals

Price / EarningsN/A
Earnings per Share-$0.89
Beta vs. S&P 500N/A
Revenue$91.2 M
Net Profit Margin-81.17%
Return on Equity-84.62%

Analyst Ratings as of 11/12/2021

Buy
7
Overweight
0
Hold
4
Underweight
0
Sell
0
Consensus RecommendationConsensus Icon
Powered by Factset